Weight loss in MASLD restores the balance of liver fatty acid sources
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lipogenesis contributes substantially to the pathological accumulation of intrahepatic triacylglycerol (IHTG) in metabolic dysfunction–associated steatotic liver disease (MASLD). Since hepatic lipogenesis is highly sensitive to energy intake, we hypothesized that mechanisms of MASLD regression induced by weight loss would be driven by a marked reduction in the lipogenic pathway. METHODS: Overweight adults with high liver fat (HighLF; n = 9; IHTG ≥ 5.6% measured by 1 H-magnetic resonance spectroscopy) or low (normal) liver fat (LowLF; n = 6; IHTG < 5.6%) received dietary counseling for 6 months and underwent comprehensive metabolic phenotyping during inpatient studies that captured fasting and fed states. Multiple stable isotopes were used to assess the contribution of lipogenesis, free fatty acids (FFAs), and dietary fat to IHTG. RESULTS: Body weight loss (–10% ± 2%) reduced IHTG in individuals with MASLD (19.4% ± 3.6% to 4.5% ± 2.1%, P < 0.001). Insulin sensitivity improved significantly (46%, P < 0.01), while fasting FFA flux from adipose tissue was not different. VLDL-triacylglycerol (VLDL-TG) concentrations fell by 38% ( P = 0.02) because of a 67% reduction in contribution from lipogenesis ( P = 0.02), whereas the absolute contributions from FFAs and dietary fat to VLDL-TG were not different. Reduced lipogenesis was significantly associated with loss of IHTG. CONCLUSION: These data underscore the primary role of lipogenesis in MASLD pathology and highlight the importance of controlling this pathway through treatment strategies. TRIAL REGISTRATION: ClinicalTrials.gov (NCT01371396). FUNDING: National Institutes of Health (NIH) grant RL1DK081187; Task Force for Obesity Research at Southwestern (TORS) NIH UL1DE019584; and Clinical and Translational Science Award NIH/National Center for Advancing Translational Sciences UL1-RR024982.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“After the 6 months of dietary intervention and marked weight reduction, VLDL-TG concentrations fell by 38% because of a 67% reduction in the contribution from DNL, whereas the contributions from FFAs and dietary fat to VLDL-TG remained unchanged compared to baseline values.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [60]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Because DNL is highly responsive to reductions in energy intake, this pathway represents the most highly modifiable biochemical contributor to MASLD [60].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [60]
In the citing paper
“Notably, weight loss resulted in a significant 75.6% relative reduction in intrahepatic TG in the H-LF group, leading to normalization of hepatic TG levels (<5.6%) in the majority of these participants (Fig. 3B) [60].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [60]
In the citing paper
“Recent studies demonstrated that diet therapy aimed at reducing total calorie and simple sugars achieved approximately 10% weight loss with a 75% reduction in hepatic TG, with normalization of liver fat in most individuals with high baseline levels.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [60]
In the citing paper
“This reduction in hepatic TG was mainly driven by suppressed hepatic DNL, rather than changes in FFA or dietary fat flux [60].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citationDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 3×
“Our original study of lipid labeling in MASLD patients demonstrated a strong association between the magnitude of stored lipid and the unlabeled lipid in VLDL-TG (12).”
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · cited 1×
“Using labeling techniques, unrestrained FFA flux from adipose tissue to the liver was shown to provide the primary source of fatty acids to IHTG, and therefore adipose insulin resistance in MASLD likely contributes to excess IHTG (9, 10).”
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347 · cited 1×
“For example, subject 4 with mild liver injury at baseline (Supplemental Figure 2A) experienced an 11% weight loss, which was associat-Currently, weight loss remains the safest and most effective treatment for MASLD (19).”
Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · cited 7×
“The DNL pathway is sensitive to excess substrate availability (fructose and glucose carbons) coupled with insulin resistance and can substantially contribute to hepatic lipid accumulation in both quantitative and qualitative ways (11, 34–36).”
InfluentialSelf-citationInsulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771 · cited 3×
“DNL is a relatively flexible biochemical pathway, correlates with the magnitude of IHTG (25), is highly responsive to energy/carbohydrate restriction, and is reduced with improvement of insulin sensitivity (26–29).”
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
Petersen, K. F., Dufour, S., Savage, D. B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G. W., Befroy, D., Zemany, L., Kahn, B. B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705408104 · Cited by 759
Fabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631
Epidemiology of chronic liver diseases in the USA in the past three decades
Younossi, Z. M., Stepanova, M., Younossi, Y., Golabi, P., Mishra, A., Rafiq, N., & Henry, L. (2020) · Gut · doi:10.1136/gutjnl-2019-318813 · Cited by 549 · cited 2×
“The prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) is rising in tandem with increasing rates of obesity and insulin resistance in the population (1–4).”
Cited by
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“For additional information, please refer to the literature [60,67].”
InfluentialMilanović, M., Milošević, N., Ružić, M., Abenavoli, L., & Milić, N. (2025) · Metabolites · doi:10.3390/metabo15080516 · Cited by 12
“Body weight loss of at least 10% may be the single most crucial feature that affects lipogenesis and inhibits the accumulation of intrahepatic triacylglycerols by reducing VLDL-triacylglycerol [45].”
Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease
Weiskirchen, R., & Lonardo, A. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671694 · Cited by 9
“This is evident through a decrease in the number and size of LDs, as well as a rebalancing of fatty acid sources and improved lipid composition within hepatocytes [133].”
Yin, H.-Y., You, Q.-H., Zhang, W.-J., Ji, G., & Dang, Y.-Q. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i6.113804 · Cited by 10
“For instance, a diet high in fat can induce MASLD through mechanisms such as fat accumulation, mitochondrial dysfunction, inflammation, and disorders of the hepato-intestinal axis[16,17].”
The thyroid-liver axis in MASLD: From metabolic control to clinical translation
Chouik, Y., Caussy, C., & Tacke, F. (2026) · Med · doi:10.1016/j.medj.2026.101173 · Cited by 4
Metadata
- Authors
- Lambert, J. E., Ramos-Roman, M. A., Valdez, M. J., Browning, J. D., Rogers, T., & Parks, E. J.
- Affiliations
- Center for Human Nutrition,
- Department of Internal Medicine,
- Department of Clinical Nutrition, and
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Parks, Elizabeth J.
- ORCID
- Parks, Elizabeth J.
- Venue
- Journal of Clinical Investigation
- Published
- 2025-05-01
- Volume
- 135
- Issue
- 9
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC12043097
- OpenAlex
- W4410004319
- Semantic Scholar
- 9c531fa254741586d886c20e4b911206a06cf39b
- Cited by
- 20
- References
- 67
- Citations by year
- 2026: 14 · 2025: 6
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (RL1DK081187, NIH UL1DE019584, NIH/NCATS UL1-RR024982)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- non-alcoholic fatty liver disease, weight loss, hepatic lipogenesis, free fatty acids, dietary fat, insulin sensitivity, caloric restriction
- MeSH terms
- Adult, Fatty Acids, Nonesterified, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Middle Aged, Triglycerides, Weight Loss, Lipogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weight loss in MASLD restores the balance of liver fatty acid sources. https://app.cochat.ai/papers/10.1172/jci174233
- The paper
- Lambert, J. E., Ramos-Roman, M. A., Valdez, M. J., Browning, J. D., Rogers, T., & Parks, E. J. (2025). Weight loss in MASLD restores the balance of liver fatty acid sources. Journal of Clinical Investigation. https://doi.org/10.1172/jci174233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.